CG
VRNA

Carlyle Group’s Verona Pharma VRNA Stock Holding History

Carlyle Group’s Portfolio VRNA Stock Details VRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,457,500
Closed -$35.5M – 31
2024
Q2 		$35.5M Hold
2,457,500
– – 3.37% 6
2024
Q1 		$39.4M Hold
2,457,500
– – 2.49% 5
2023
Q4 		$48.8M Hold
2,457,500
– – 2.35% 6
2023
Q3 		$40M Hold
2,457,500
– – 1.74% 8
2023
Q2 		$51.9M Hold
2,457,500
– – 1.85% 5
2023
Q1 		$49.3M Buy
+2,457,500
New +$53.1M 1.47% 8

Other funds holding VRNA

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Carlyle Group's VRNA Position: Q3 2024 in Review

Carlyle Group sold out of Verona Pharma (VRNA) in Q3 2024, closing a stake of 2,457,500 shares — an estimated $35.5M sold.

Carlyle Group first reported a position in VRNA in Q1 2023 and held it in 6 quarters. The position peaked at $51.9M in Q2 2023. 150 funds tracked by Wall St. Rank hold VRNA as of Q3 2024.

  • Carlyle Group reported no remaining Verona Pharma position as of Q3 2024 after selling out during the quarter.
  • Carlyle Group sold 2,457,500 Verona Pharma shares in Q3 2024, an estimated $35.5M.
  • Carlyle Group first reported a position in Verona Pharma in Q1 2023 and held it in 6 quarters.
  • Carlyle Group's Verona Pharma position peaked at $51.9M in Q2 2023.
  • 150 funds tracked by Wall St. Rank held Verona Pharma as of Q3 2024.

Based on Carlyle Group's 13F filing for Q3 2024, filed 8 Nov 2024.